Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dutasteride/Tamsulosin FDC vs Coadministration in Healthy Males
NCT02509104Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alpha blocker + 5-alpha reductase inhibitor in benign prostatic hyperplasia (BPH) (2 cohorts), sponsored by GSK. Primary endpoints: Maximum observed serum concentration, Area under the serum concentration-time curve zero to time 't' and 1 more. Started Jul 2015; status: completed.
02
Drugs
alpha blocker + 5-alpha reductase inhibitor
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02509104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509104.